ANGIOSARCOMA

This study aimed to find a safe dose of a custom-made mRNA vaccine for people with a rare skin cancer called cutaneous angiosarcoma. The vaccine was designed to train the immune system to attack the cancer. However, the trial was withdrawn before any participants were enrolled.

This phase 2 trial is testing a combination of two immunotherapy drugs, nivolumab and ipilimumab, in 798 people with over 50 types of rare cancers. The goal is to see if these drugs can shrink tumors by helping the immune system attack cancer cells. Participants receive the drugs…

This study tests a new treatment for angiosarcoma, a rare and aggressive cancer of the blood vessels. The treatment combines a virus that is injected directly into tumors (vusolimogene oderparepvec) with an immunotherapy drug (pembrolizumab). The goal is to see if this combinatio…

This study tests whether combining two drugs, lenvatinib and pembrolizumab, can safely shrink or control advanced soft tissue sarcomas that have spread or can't be removed by surgery. About 52 adults with specific sarcoma types will receive the combination. The goal is to measure…

This early-phase study tests two experimental immunotherapy drugs — botensilimab and balstilimab — alone and together in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check safety, find the right dose, and look for ea…

This phase 2 study tests two drugs, sunitinib and temsirolimus, in 137 people with advanced rare tumors that have no cure. The goal is to see if these drugs can shrink tumors or slow their growth. Participants take one of the two drugs, and researchers measure how long the cancer…

This small pilot study tested the drug eribulin (Halaven) in 13 people with two rare cancers of blood vessels: angiosarcoma and epithelioid hemangioendothelioma (EHE). The goal was to see if the drug could shrink tumors or stop them from growing. Participants had already tried at…